Drug profile · INN
fluticasone furoate
ARNUITY ELLIPTA
fluticasone furoate (ARNUITY ELLIPTA) is a glucocorticoid receptor agonist. Associated with GlaxoSmithKline. Route of administration: nasal. Current US regulatory status: approved.
Drug details — fluticasone furoate
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- NASAL
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
fluticasone furoate (ARNUITY ELLIPTA) is a glucocorticoid receptor agonist. Associated with GlaxoSmithKline. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fluticasone furoate?
fluticasone furoate (ARNUITY ELLIPTA) is a glucocorticoid receptor agonist. Associated with GlaxoSmithKline. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for fluticasone furoate?
ARNUITY ELLIPTA is a marketed brand name for fluticasone furoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fluticasone furoate?
fluticasone furoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.